Welcome to our dedicated page for KORU Medical Systems SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KORU Medical Systems's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KORU Medical Systems's regulatory disclosures and financial reporting.
BlackRock, Inc. reports beneficial ownership of common stock of KORU MEDICAL SYSTEMS INC. BlackRock and certain of its subsidiaries and affiliates collectively hold 2,575,761 shares of KORU common stock, representing 5.6% of the class.
BlackRock has sole voting power over 2,537,482 shares and sole dispositive power over 2,575,761 shares, with no shared voting or dispositive power reported. Various underlying clients and investors have rights to dividends or sale proceeds, but no single such person is reported to hold more than five percent of KORU’s outstanding common shares. The filing is signed by a BlackRock managing director.
KALBERMATTEN ADAM R reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems, Inc. reported that President and CEO Adam R. Kalbermatten received a grant of 284,091 Performance Stock Units tied to long-term performance goals. According to the award terms, 213,068 units may vest based on a target for the company’s net sales growth on or prior to 12/31/2030, and 71,023 units may vest based on achieving a specified market capitalization target as of 12/31/2030. The award represents a performance-based equity incentive linked to both operating and market outcomes.
KALBERMATTEN ADAM R reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems reported that President and CEO Adam R. Kalbermatten received a grant of 286,697 Performance Stock Units, each tied to an equal number of common shares. These awards were made under his amended and restated employment agreement as part of equity-based compensation.
According to the performance terms, 215,023 units may vest based on achieving a target level of the company's net sales growth on or prior to 12/31/2030, and 71,674 units may vest based on reaching a specified company market capitalization at 12/31/2030. All 286,697 units are reported as directly held following this grant.
KORU Medical Systems director Edward Wholihan received a grant of 3,571 shares of Common Stock, valued at $4.20 per share. This is a compensation-related award reported as an acquisition, not an open-market purchase. After the grant, his direct ownership totals 51,312 shares.
KORU Medical Systems director Matin Shahriar received a grant of common stock as part of equity compensation. On the reported date, Shahriar acquired 3,571 shares of KORU Medical Systems, Inc. common stock at $4.20 per share in a non-derivative award transaction.
Following this grant, Shahriar directly holds 101,144 shares of KORU Medical Systems common stock. This filing reflects a stock award rather than an open-market purchase or sale.
French Donna reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Donna French received a grant of 3,571 shares of Common Stock at $4.20 per share. This was a compensation-related award, not an open-market purchase. Following the grant, she directly holds a total of 98,514 KORU Medical Systems shares.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director R. John Fletcher received a grant of 5,357 shares of Common Stock at $4.20 per share. This was a compensation-related award rather than an open-market purchase. After the grant, he directly owns 232,157 shares, indicating the award is a relatively small addition to his existing position.
CASCELLA ROBERT reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Robert Cascella received a grant of 3,571 shares of Common Stock at $4.20 per share as a compensation-related award. After this Form 4 transaction, he directly owns 98,155 shares of KORU Medical Systems common stock.
KORU Medical Systems director and major holder reports stock grant. A Form 4 shows an entity associated with Horton Capital receiving a grant or other acquisition of 3,571 shares of KORU Medical common stock at $0.00 per share.
After this grant, Horton Capital Partners Fund, L.P. is reported with 5,069,541 shares held indirectly, while Joseph M. Manko Jr. also reports 782,547 shares held directly. The filing reflects a compensation or award-type acquisition rather than an open-market purchase or sale.
KORU Medical Systems, Inc. entered into Amendment No. 1 to its Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, LLC. Command manufactures and supplies KORU’s subassemblies, needle sets and tubing products under this agreement.
The amendment extends the initial term so the agreement now runs through December 31, 2031, with automatic one-year renewals unless either party gives at least 180 days notice not to renew. It also revises pricing and payment terms, including product pricing, annual price adjustments and pass-through cost savings.
The amendment adds requirements for Command to obtain and qualify a second manufacturing site by December 31, 2027, and gives KORU a new right to terminate if Command misses this requirement and does not cure within 30 days. Command becomes the exclusive manufacturer of a limited set of products, wind-up period provisions are broadened, intellectual property ownership and licenses are clarified, assignment rights are made mutual, and a prior non-competition provision is removed. Other termination rights, including for uncured material breach within 45 days, bankruptcy or insolvency, and force majeure events lasting at least 30 days, remain in place.